MICROBIOLOGY.
For the article ''Leishmania disease development depends on the presence of apoptotic promastigotes in the virulent inoculum,'' by Ger van Zandbergen, Annalena Bollinger, Alexander Wenzel, Shaden Kamhawi, Reinhard Voll, Matthias Klinger, Antje Müller, Christoph Hölscher, Martin Herrmann, David Sacks, Werner Solbach, and Tamás Laskay, which appeared in issue 37, September 12, 2006 , of Proc Natl Acad Sci USA (103:13837-13842; first published August 31, 2006; 10.1073͞pnas.0600843103), due to a printer's error, Fig. 1 was incorrect as shown. The corrected figure and its legend appear below. Cell killing is a critical pharmacological activity of imatinib to eradicate Bcr͞Abl ؉ leukemias. We found that imatinib kills Bcr͞ Abl ؉ leukemic cells by triggering the Bcl-2-regulated apoptotic pathway. Imatinib activated several proapoptotic BH3-only proteins: bim and bmf transcription was increased, and both Bim and Bad were activated posttranslationally. Studies using RNAi and cells from gene-targeted mice revealed that Bim plays a major role in imatinib-induced apoptosis of Bcr͞Abl ؉ leukemic cells and that the combined loss of Bim and Bad abrogates this killing. Loss of Bmf or Puma had no effect. Resistance to imatinib caused by Bcl-2 overexpression or loss of Bim (plus Bad) could be overcome by cotreatment with the BH3 mimetic ABT-737. These results demonstrate that Bim and Bad account for most, perhaps all, imatinibinduced killing of Bcr͞Abl ؉ leukemic cells and suggest previously undescribed drug combination strategies for cancer therapy.
apoptosis ͉ imatinib mesylate ͉ Bcl-2 ͉ cancer ͉ leukemia T he Bcr͞Abl fusion oncoprotein, the product of the reciprocal t(9, 22)(q34;q22) chromosomal translocation [Philadelphia (Ph 1 ) chromosome], is essential for leukemogenesis in chronic myelogenous leukemia (CML) and Ph 1 -positive acute lymphoblastic leukemias. The constitutive tyrosine kinase activity of Bcr͞Abl promotes malignant transformation by activating signaling pathways that stimulate uncontrolled cell proliferation, abnormal cell adhesion, and resistance to many apoptotic stimuli, including various anticancer agents (1) . The blockade of Bcr͞Abl is thought to be the most promising therapeutic approach for CML, exemplified by the dramatic clinical efficacy of imatinib mesylate (imatinib, Gleevec, Glivec, and STI 571) (1) . By blocking Bcr͞Abl kinase activity, imatinib inhibits cell proliferation and induces apoptosis (1, 2) .
Mammals have two distinct apoptosis-signaling pathways that converge upon activation of a family of aspartate-specific cysteine proteases (caspases), which mediate cell demolition (3). One of these pathways is triggered by ligation of so-called ''death receptors'' (members of the TNF-R family with an intracellular ''death domain'') and requires FADD-mediated activation of caspase-8 (3). The other pathway, activated by developmental signals or certain cytotoxic drugs, is regulated by the interplay of pro-and antiapoptotic members of the Bcl-2 protein family and involves mitochondrial release of apoptogenic molecules (e.g., cytochrome c) for caspase activation and cell demolition (4). The Bcl-2 protein family contains three major subgroups. Antiapoptotic members, including Bcl-2, Bcl-x L , Bcl-w, Mcl-1, and A1, share four regions of homology (Bcl-2 Homology or BH regions). Bax, Bak, and Bok contain BH1, 2, and 3 regions and, although they have remarkable structural similarity to their prosurvival relatives, these proteins are essential for cell killing (3, 4) . The BH3-only proteins (Bad, Bik, Bid, Bim, Hrk, Bmf, Noxa, and Puma) have only the 9-to 16-aa BH3 region and are regulated by a range of transcriptional and posttranslational mechanisms (5) . Experiments with gene-targeted mice have shown that different BH3-only proteins are required for apoptosis initiation in response to distinct developmental cues and cytotoxic stimuli (6) .
Previous work has shown that overexpression of Bcl-2 or Bcl-xL (7) and, to a lesser extent, RNAi-mediated reduction in Bim (8, 9) , inhibits imatinib-induced killing of Bcr͞Abl ϩ leukemic cells. We demonstrate here that imatinib activates not only Bim, but also Bad and Bmf, and we show that Bim plus Bad account for most, perhaps all, imatinib-induced killing of Bcr͞Abl ϩ leukemic cells. Remarkably, resistance caused by Bcl-2 overexpression or loss of Bim plus Bad can be overcome by cotreatment with the BH3 mimetic ABT-737. These results provide insight into the mechanisms of imatinib-induced cell killing and suggest rational therapeutic approaches for Bcr͞Abl ϩ leukemias and possibly also other tumors.
Results
Imatinib Activates the Bcl-2-Regulated Apoptotic Pathway in Bcr͞Abl ؉ Leukemic Cell Lines. The Bcr͞Abl ϩ human leukemia lines K562 and BV173 were chosen for initial studies on the effects of imatinib. Imatinib inhibited the proliferation of both cell lines, as reflected by decreased metabolic activity (MTS assay) (Fig. 6a , which is published as supporting information on the PNAS web site). Whereas most K562 cells had undergone apoptosis within 48 h, the BV173 cells were more resistant, as measured by staining with vital dyes and annexin V ( Fig. 6b ; see Fig. 7 , which is published as supporting information on the PNAS web site). Western blot analysis showed that Bcl-2 levels dropped significantly in imatinib-treated K562 cells but remained stable, or even increased slightly, in BV173 cells. The level of Bcl-x L was significantly higher in BV173 cells than in K562 cells, and imatinib treatment caused no obvious change in Bcl-x L , Mcl-1, or Bcl-w levels in either cell line (Fig. 6c) . In contrast, a previous report (10) indicated that imatinib causes a reduction in Bcl-x L in K562 cells, and we speculate that this difference is explained by clonal variation amongst distinct K562 isolates. Re-gardless, both results suggest that imatinib kills K562 cells by activating the intrinsic, Bcl-2 family regulated apoptosis pathway and that sustained high levels of Bcl-2 and Bcl-x L may account for the greater resistance of BV173 compared with K562 cells. This hypothesis was confirmed by showing that enforced expression of Bcl-2 or Bcl-x L protected K562 cells in a dose-dependent manner from the proapoptotic effects of imatinib, whereas a dominantinterfering mutant of FADD͞MORT1, which blocks deathreceptor signaling, had no effect (Fig. 6 d-f ).
Imatinib Increases Bim Expression in Bcr͞Abl ؉ Leukemia Cell Lines. To further explore how imatinib activates apoptosis, we examined the effect of imatinib on the expression of BH3-only proteins, distant proapoptotic relatives of Bcl-2 (6). Treatment with imatinib induced a rapid and sustained increase in the levels of Bim EL and, to a lesser extent, also Bim L in K562 (Fig. 1a) and BV173 (Fig. 1b) cells. When K562 cells were pretreated with the pan-caspase inhibitor Z-VAD-fmk, imatinib still elicited a marked increase in Bim EL and Bim L (Fig. 8 , which is published as supporting information on the PNAS web site).
Semiquantitative RT-PCR (Fig. 1c) and quantitative PCR analysis revealed that imatinib treatment increased bim mRNA levels by Ϸ3-fold in K562 cells within 3 h. We also noted that Bim EL protein from imatinib-treated K562 cells migrated more rapidly in SDS͞PAGE than Bim EL from untreated cells (Fig. 1a) , suggesting a loss of phosphorylation, which is known to increase Bim's proapoptotic activity in cytokine-deprived cells (11) (12) (13) . Two-dimensional gel electrophoresis and Western blotting demonstrated that imatinib treatment caused the disappearance of the most negatively charged Bim EL proteins (arrows) in K562 cells, indicating the accumulation of hypophosphorylated forms of Bim (Fig. 1d ). This reduction in Bim phosphorylation is probably a consequence of loss of ERK activity caused by Bcr͞Abl blockade (Fig. 9 , which is published as supporting information on the PNAS web site). These results show that imatinib increases Bim levels in a caspase-independent manner by up-regulating mRNA levels and by posttranslational modification.
Bim Is a Critical but Not the Sole BH3-only Protein Mediating Imatinib-
Induced Killing of Bcr͞Abl ؉ Leukemic Cell Lines. To examine the role of Bim in imatinib-induced cell killing, we first generated multiple subclones of K562 and BV173 cells in which Bim levels were suppressed to various extents by stable expression of an RNAi construct (Fig. 2a) . Expression of a control RNAi construct had no effect on cell proliferation, Bcr͞Abl expression, or the response to imatinib (Fig. 10 , which is published as supporting information on the PNAS web site). In contrast, Bim knockdown reduced the susceptibility to imatinib-induced killing, and the extent of Bim suppression correlated with the extent of protection from imatinibinduced cell killing ( Fig. 2 b and c) .
To examine the role of Bim in long-term survival and retention of proliferative capacity, parental K562 cells, Bim knockdown K562 (subclone #18), or Bcl-2 overexpressing cells (H: high level ϭ K562͞Flag-bcl-2.puro.H.) were treated for 24 or 48 h with imatinib, washed, and then plated in agar to enumerate surviving, clonogenic cells. Bim knockdown significantly rescued clonogenic potency, with K562͞shBim#18 cells forming twice or Ͼ10 times as many colonies as parental K562 cells after 24 or 48 h of imatinib treatment, respectively (Fig. 2d ). Bcl-2 overexpression promoted even greater retention of clonogenic potential (Fig. 2d) .
This observation and the finding that many Bim knockdown cells eventually died after exposure to imatinib (Fig. 2b) indicated that the residual amount of Bim in these cells might be sufficient for cell killing. Alternatively, additional proapoptotic factors might contribute to imatinib-induced cell killing. We found that Bim levels were increased after imatinib treatment, even in K562͞shBim#18 and BV173͞shBim#4 clones, although basal levels were almost undetectable (Fig. 3a) . In addition, we observed that Bad became dephosphorylated and that Bmf was up-regulated in response to imatinib treatment in parental and Bim knockdown BV173 cells and, to a lesser extent, also in K562 cells (Fig. 3a) . Semiquantitative RT-PCR and quantitative PCR analysis in K562 cells showed that imatinib caused Ϸ7-fold increased transcription of bmf but not puma (Fig. 3b) , a BH3-only gene implicated in chemotherapeutic drug-induced apoptosis (14, 15) . These results indicate that Bim is critical for imatinib-induced apoptosis in Bcr͞Abl ϩ leukemic cell lines and suggest that additional BH3-only proteins, particularly Bad and Bmf, also may contribute to cell killing.
Combined Loss of Bim and Bad Prevents Imatinib-Induced Killing of Bcr͞Abl-Transformed Mouse Fetal Liver-Derived Myeloid Progenitors.
To avoid the complication of incomplete loss of protein expression in RNAi vector-transfected cells, we took advantage of BH3-only gene knockout mice. Fetal liver-derived hemopoietic cells from wt, (embryonic day 14.5) were transformed with a bcr-abl retrovirus and clonal lines expressing bcr-abl mRNA derived for tests of sensitivity to imatinib. At least three independent clones from each genetic background were assessed; each had a morphology (Fig. 11 , which is published as supporting information on the PNAS web site) and surface marker expression that was characteristic of myeloid progenitors (e.g., Sca-1, c-Kit, and Sca-2). Imatinib inhibited proliferation and induced death in wt.bcr-abl ϩ cells in a time-and dose-dependent manner (Fig. 4) . Loss of Bim and, to a somewhat lesser extent, loss of Bad conferred resistance to imatinib-induced cell death (Fig. 4b) . This effect was specific because bcr-abl transformed myeloid progenitors lacking Bmf or Puma, a BH3-only protein required for the proapoptotic effects of etoposide and dexamethasone (14, 15) , remained as sensitive to imatinib as wt.bcr-abl transformed cells (Fig. 12 , which is published as supporting information on the PNAS web site).
Consistent with the notion that Bim and Bad are activated independently by imatinib, we found similar induction of Bim in wt and bad Ϫ/Ϫ bcr-abl transformed myeloid progenitors, and similar loss of phosphorylation of Bad was seen in wt and bim Ϫ/Ϫ cells (Fig.  13 , which is published as supporting information on the PNAS web site). In addition, imatinib caused Bmf up-regulation in lines of all genotypes (although induction in bim Ϫ/Ϫ lines was variable) but had no impact on the levels of puma mRNA or Bcl-2, Bcl-x L , and Bax protein (Fig. 13) .
Because many of the bcr-abl transformed bim Ϫ/Ϫ and bad Ϫ/Ϫ cells eventually died after treatment with imatinib (Fig. 4b) , we hypothesized that these two BH3-only proteins might have overlapping function. Strikingly, Ͼ90% of the bcr-abl-transformed bim Ϫ/Ϫ bad Ϫ/Ϫ fetal liver cells remained viable even after 7 days of exposure to 3 M imatinib, a degree of resistance that was only recapitulated by Bcl-2 overexpression (Fig. 4b) . These cells, however, did undergo growth arrest (Fig. 4a) , demonstrating that the drug was able to inhibit its target in these cells. These results demonstrate that Bim plus Bad account for most, perhaps all, imatinib-induced killing of bcr-abl transformed cells. De novo or acquired resistance to chemotherapeutic drugs is a significant problem in the treatment of CML and other cancers (1, 2) . Up-regulation of prosurvival Bcl-2-like proteins or loss of their proapoptotic relatives has been shown to influence responses to cancer therapy (3, 4) . Recently, it has been reported that a BH3-mimetic compound, ABT-737, which binds to Bcl-2, Bcl-x L , and Bcl-w, can kill certain tumor cells when used alone or in combination with chemotherapeutic drugs (16) . Because the loss of Bim and͞or Bad, or Bcl-2 overexpression rendered 
Bcr͞Abl
ϩ leukemic cells resistant to imatinib, we wondered whether ABT-737 could resensitize them. We therefore treated parental K562 cells and subclones overexpressing Bcl-2 or those with suppressed levels of Bim for 48 h with either drug alone or in combination and then measured their survival. By itself, ABT-737 had relatively little effect on any of the K562 sublines (maximum 25% cell killing). Significantly, however, its addition greatly enhanced imatinib-induced cell death; 5 M ABT-737 increased killing by imatinib (1 M; open squares) of both Bcl-2 overexpressing and Bim-deficient K562 cells from 10-20% to Ϸ70% (Fig. 5a) . Even more remarkably, although bcr-abl-transformed bim Ϫ/Ϫ bad Ϫ/Ϫ myeloid progenitors cells were refractory to imatinib (1. cell number (10 6 /ml) cell number (10 6 /ml) cell number (10 6 /ml) cell number (10 6 /ml) cell number (10 6 /ml) M, open triangles; 3 M, closed triangles), cotreatment with as little as 2.5 M ABT737 resulted in Ͼ90% killing of these cells (Fig.  5b) . This synergy between imatinib and ABT-737 appeared to be specific for Bcr͞Abl ϩ cells, because normal human hepatocytes treated in culture with 3 M imatinib plus 5 M ABT-737 retained Ͼ90% viability (Fig. 14 , which is published as supporting information on the PNAS web site). These results demonstrate that cotreatment with the BH3 mimetic ABT-737 can overcome resistance of Bcr͞Abl-transformed cells to imatinib caused by loss of Bim and Bad or Bcl-2 overexpression.
Discussion
Imatinib has shown remarkable clinical benefit for treatment of Bcr͞Abl ϩ leukemia, especially CML patients in early chronic phase. However, it has become clear that rare clones with mutations that confer resistance to imatinib (e.g., mutations in bcr-abl that prevent imatinib binding) can survive, and this resistance can lead to relapse and limits the effects for patients with advanced disease (1) .
Because the inhibition of cell proliferation by the blockade of Bcr͞Abl with imatinib is not sufficient for eradicating Bcr͞Abl ϩ leukemic clones, a better understanding of the mechanisms by which imatinib kills cells and how this killing can be augmented may lead to improved therapeutic strategies. Although, our study confirmed that Bcl-2 or Bcl-x L overexpression (7) or RNAi-mediated reduction of Bim (8, 9) inhibits imatinib-induced apoptosis in K562 cells, we found that it is the combination of Bim and Bad that accounts for the killing activity of imatinib. Imatinib caused a marked reduction in Bcl-2 in the highly sensitive K562 cells, whereas Bcl-2 was maintained at high levels in the more-resistant BV173 cells. Because Bcl-2 overexpression affords protection, it appears likely that Bcl-2 reduction contributes to the high sensitivity of K562 cells to imatinib. The imatinib-induced reduction in Bcl-2 in K562 cells may be a consequence of Stat5 inhibition, a transcription factor activated by Bcr-Abl and known to promote bcl-2 transcription (17).
In agreement with published data (8, 9), we found that imatinib caused up-regulation of Bim protein levels in two Bcr͞Abl ϩ human leukemic cell lines and in bcr-abl-transformed mouse myeloid progenitor lines. Transcriptional up-regulation of Bim was reported to be mediated by FOXO3A (9) , and it appears likely that this transcription factor is activated by imatinib because of shutdown of PI3k͞Akt signaling, a Bcr͞Abl-stimulated pathway known to suppress FOXO3A activity (18) . Our 2D gel electrophoresis analyses indicate that posttranslational activation of Bim also contributes to imatinib-induced cell killing. Most likely, imatinib causes loss of Bim phosphorylation by diminishing the activity of Erk, a Bcr͞Abl-activated kinase that is known to inhibit Bim's proapoptotic activity by phosphorylating Bim, thereby targeting it for ubiquitination and proteasomal degradation (11) (12) (13) .
Reduction of Bim expression by using stable expression of an RNAi vector promoted not only short-term survival, as reported in refs. 8 and 9, but even enhanced clonogenic survival of imatinibtreated K562 cells. Many of the Bim knockdown cells, however, did die after prolonged exposure to imatinib, raising the question whether Bim is the only BH3-only protein that initiates apoptosis. Because the levels of Bim in many of the imatinib-treated Bim knockdown clones still were lower than the basal levels of Bim found in untreated parental K562 and BV173 cells, it appeared more likely that Bim cooperates with other proapoptotic proteins. Indeed, in K562 cells and bcr-abl transformed murine myeloid progenitor lines, imatinib caused increased expression of Bmf (19) and substantial dephosphorylation of Bad, a process known to enhance its proapoptotic activity (20) . Bad dephosphorylation is likely to be a consequence of a shutdown of the PI3k͞Akt and͞or Ras͞Raf-1͞Mek͞Erk pathways (both Bcr͞Abl targets), which are known to inhibit the proapoptotic activity of Bad (20) .
To systematically examine the role of BH3-only proteins in imatinib-induced cell killing, we generated bcr-abl-transformed myeloid progenitor lines from fetal liver of mice lacking Bim, Bad, or both. Loss of Bim provided substantial but incomplete protection against imatinib-induced cell death. These observations indicate that the death of the human leukemic cell lines was not due to merely residual levels of Bim. Loss of Bad also provided partial protection against imatinib and, remarkably, all bcr-abl transformed bim Ϫ/Ϫ bad Ϫ/Ϫ cell lines were highly resistant to imatinib-induced cell killing. These results are consistent with the notion that Bcr͞Abl inhibits apoptosis in Bcr͞Abl ϩ leukemic cells by keeping both Bim and Bad in check. The finding that Bim loss affords greater protection against imatinib than Bad deficiency can be explained by the fact that Bim binds all prosurvival Bcl-2 family members with high affinity, whereas Bad interacts only with a subset (21) . Bmf was induced in imatinib-treated bcr-abl-transformed bim Ϫ/Ϫ and bad Ϫ/Ϫ cells, but bcr-abl transformed murine myeloid progenitors lacking Bmf or Puma normally were sensitive to imatinib. Given the critical role of Bim in imatinib-induced apoptosis of bcr-abl-transformed leukemic cells in culture, it will be interesting to examine whether imatinib induces Bim in primary CML in vivo and whether imatinibresistant CML cells with unmutated bcr-abl have abnormalities in their bim genes or in genes encoding upstream regulators of Bim, such as FOXO3A.
How to augment the therapeutic effect of imatinib or other Bcr͞Abl kinase inhibitors is a topic of great interest (1) . With respect to studies on combination therapies, inhibitors of the Ras͞Mek͞Erk or the PI3k͞Akt͞mTOR pathways have been reported to act synergistically with imatinib (22) . Our results may explain these synergistic effects, because these inhibitors are expected to enhance activation of Bim and Bad by transcriptional and͞or posttranslational mechanisms, such as FOXO3A-mediated induction of bim mRNA synthesis, and loss of Bim and Bad phosphorylation due to inactivation of Erk and Akt kinases.
Our studies put forward an attractive strategy for additional improvements in the treatment of CML: the use of BH3 mimetic compounds to inhibit the action of antiapoptotic Bcl-2 family members, thereby leading to Bax͞Bak activation (16) . Our data show that the BH3 mimetic ABT-737 enhances imatinib-induced killing of bcr-abl ϩ human and mouse leukemic cells and even can overcome resistance to imatinib caused by Bcl-2 overexpression or loss of Bim and͞or Bad. This approach may be relevant particularly for imatinib-resistant CML with unmutated bcr-abl, which undergo proliferation arrest but not death in response to treatment (1), particularly if changes in Bcl-2 family are shown to play a role. Perhaps, combined imatinib͞ABT-737 treatment may also be advantageous for primary treatment of imatinib-sensitive CML to enhance eradication of the neoplastic clone, because some authors have hypothesized that imatinib acts predominantly by inhibiting proliferation of leukemic cells (2) . ABT-737-induced cell killing therefore may help prevent emergence of (bcr-abl) mutated subclones, thereby producing longer remission or even cure. Finally, our studies suggest that combined treatment with a cell deathinducing BH3 mimetic plus a specific inhibitor of the product of an oncogene causative of transformation in a particular tumor (i.e., Bcr͞Abl in CML or B-Raf in melanoma) may be a more generally applicable strategy for treatment of other types of cancer.
Materials and Methods
Cell Lines, Expression Constructs, and Cell Transfection. Cells were maintained as suspension cultures in RPMI medium 1640 with 10% or 15% heat-inactivated FCS and 2 mM L-glutamine. Expression constructs for human Bcl-2, Bcl-x L , and a dominant-interfering mutant of FADD͞MORT1, all containing an N-terminal FLAG epitope tag and the puromycin resistance gene were described in ref. 23 . A Gene Pulser (Bio-Rad Laboratories, Hercules, CA) was used for electroporation, and transfected cells were selected with 5 g͞ml puromycin. Cells were single-cell cloned by limiting dilution. FLAG-tagged proteins were detected by cytoplasmic immunofluorescence staining with anti-FLAG antibody (M2; Sigma, St. Louis, MO) and flow cytometric analysis in a FACScan (Becton Dickinson, Franklin Lakes, NJ).
Generation of the anti-Bim short hairpin RNA construct cloned into pSUPER vector with the neomycin-resistant gene was described in ref. 24 .
Mice and Retroviral Infection of Fetal Liver-Derived Hemopoietic Cells.
All experiments with mice were performed according to the guidelines of the Melbourne Health Research Directorate Animal Ethics Committee. The bim Ϫ/Ϫ (25), bad Ϫ/Ϫ (26), puma Ϫ/Ϫ (14), and vav-bcl-2 transgenic (27) mice have all been described, but not bmf Ϫ/Ϫ mice (A.V. and A.S., unpublished work). These animals either were generated on a C57BL͞6 background or had been backcrossed with C57BL͞6 mice for more than eight generations. The bim Ϫ/Ϫ bad Ϫ/Ϫ mice were produced by intercrossing bim Ϫ/Ϫ and bad Ϫ/Ϫ mice. Fetal liver cells were harvested from 14.5-day-old embryos and precultured for 24 h in DMEM containing 20% FCS, 2 mM L-glutamate, 50 M 2-mercaptoethanol, and cytokines (50 ng/ml stem cell factor͞50 ng/ml thrombopoietin͞500 ng/ml fetal liver kinase-ligand͞100 units/ml IL-6; all gifts of W Alexander, The Walter and Eliza Hall Institute of Medical Research). The pMPZen.bcr-abl expression vector has been described in ref. 28 and was transfected into packaging Phoenix cells by using FuGENE6 (Roche, Indianapolis, IN). Precultured fetal liver cells were infected by cocultivation on Retronectin (Takara, Kusatsu, Japan)-coated plates in virus-containing medium supplemented with cytokines (see above). Infected cells expressing Bcr͞Abl were selected by growth in the absence of cytokines.
Western Blotting. Western blotting was performed with antibodies against Abl (clone 8E9; BD Pharmingen, Franklin Lakes, NJ), human Bcl-2 (Bcl-2-100), mouse Bcl-2 (clone 3F11), Bcl-w (clone 13F9; Alexis, Lausen, Switzerland), Bcl-x L (Transduction Laboratory, Lexington, KY), Bim (clone 3C5, Alexis; or polyclonal Ab from Stressgen, Victoria, BC, Canada), Bad (Stressgen), phosphoBad (Ser 112 ), phospho-Bad (Ser 136 ) (both from Cell Signaling Technology, Beverly, MA), Bax (Upstate Biotechnology, Lake Placid, NY), mouse Bmf (clone 12E10, Alexis), human Bmf (polyclonal Ab; Alexis), Heat Shock Protein 70 (Hsp70) (N6; a gift from R. Anderson, Peter MacCallum Cancer Institute, Melbourne, Australia), Mcl-1 (Dako, Glostrup, Denmark) and ␤-actin (Sigma) were used. Detection was performed with HRP-conjugated secondary Abs (specific to rat, mouse, hamster, or rabbit IgG) and enhanced chemiluminescence (Amersham Biosciences). Two-Dimensional Gel Electrophoresis. Two-dimensional protein electrophoresis was performed by using the IPGphor isoelectric focusing (IEF) system (Amersham Biosciences, Piscataway, NJ). Protein lysates were loaded onto IPG gels, rehydrated at 20°C for 12 h, and subjected to IEF for at least 12,000 volt ϫ h. After equilibration with SDS͞PAGE buffer for 10 min at room temperature, the IPG gel was subjected to SDS͞PAGE. Transfer, immunoblotting, and visualization were performed as described above.
RT-PCR. Total RNA was extracted by using the Microto-Midi Total RNA Extraction Kit (Invitrogen, San Diego, CA), and 40 ng͞l total RNA (in a volume of 25 l) was subjected to RT. One microliter of the resulting cDNA was subjected to PCR by using primers for bim, bcr͞abl, bmf, or puma or ␤-actin as a control for the quality and abundance of RNA (sequences will be provided upon request).
Cell Death Assays. Cell death was assessed either by trypan blue staining and cell counting in a hemocytometer or by staining with propidium iodide (PI) with or without costaining with annexin V-FITC and flow cytometric analysis. The MTS assay was performed with the cell proliferation assay kit (MBL, Nagoya, Japan) according to the manufacturer's instructions. For clonogenic survival assays, K562 cells were seeded at 2.0 ϫ 10 5 cells per ml and treated with 1.5 or 3 M imatinib (Novartis Pharma, Basel, Switzerland) for 24 or 48 h. Cells then were washed three times in complete medium to remove imatinib and before plating on 0.3% soft agar containing 20% FCS and 30% DMEM. Clonogenic potency was examined by counting colony numbers after 8 days of culture.
